The integration of artificial intelligence into medical practice faces a fundamental regulatory challenge that could reshape how we validate healthcare innovations. Traditional clinical trials, designed for static interventions like pharmaceuticals, are proving inadequate for AI systems that continuously learn and evolve from patient data. This mismatch threatens to either stifle AI advancement through inappropriate oversight or compromise patient safety through insufficient validation. Nature Medicine addresses the urgent need for adaptive trial methodologies that can accommodate AI systems requiring ongoing refinement. Unlike conventional medical devices that remain unchanged post-approval, AI algorithms improve through exposure to new data patterns, necessitating frameworks that can evaluate moving targets rather than fixed interventions. The proposal centers on continuous monitoring protocols that track AI performance metrics in real-time while maintaining regulatory compliance. This represents a significant departure from the binary approve-or-reject model that has governed medical innovation for decades. The implications extend beyond regulatory science into practical healthcare delivery. Hospitals and clinics implementing AI tools need assurance that ongoing algorithm updates maintain safety and efficacy standards without requiring complete re-validation for each modification. The challenge lies in balancing innovation velocity with patient protection. While the framework promises to accelerate beneficial AI deployment, it also introduces complexity around accountability, version control, and adverse event attribution. Success will require unprecedented cooperation between technologists, clinicians, and regulators to establish standards that neither paralyze innovation nor compromise the rigorous safety expectations that define modern medicine.